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Oxytocin’s neurochemical effects in the medial prefrontal
cortex underlie recovery of task-speciﬁc brain activity in
autism: a randomized controlled trial
Y Aoki1, T Watanabe1,2, O Abe3,4, H Kuwabara5, N Yahata1, Y Takano1, N Iwashiro1, T Natsubori1, H Takao3, Y Kawakubo5, K Kasai1 and
H Yamasue1,6
The neuropeptide oxytocin may be an effective therapeutic strategy for the currently untreatable social and communication deﬁcits
associated with autism. Our recent paper reported that oxytocin mitigated autistic behavioral deﬁcits through the restoration of
activity in the ventromedial prefrontal cortex (vmPFC), as demonstrated with functional magnetic resonance imaging (fMRI) during
a socio-communication task. However, it is unknown whether oxytocin exhibited effects at the neuronal level, which was outside of
the speciﬁc task examined. In the same randomized, double-blind, placebo-controlled, within-subject cross-over clinical trial in
which a single dose of intranasal oxytocin (24 IU) was administered to 40 men with high-functioning autism spectrum disorder
(UMIN000002241/000004393), we measured N-acetylaspartate (NAA) levels, a marker for neuronal energy demand, in the vmPFC
using 1H-magnetic resonance spectroscopy (1H-MRS). The differences in the NAA levels between the oxytocin and placebo sessions
were associated with oxytocin-induced fMRI signal changes in the vmPFC. The oxytocin-induced increases in the fMRI signal could
be predicted by the NAA differences between the oxytocin and placebo sessions (P= 0.002), an effect that remained after
controlling for variability in the time between the fMRI and 1H-MRS scans (P= 0.006) and the order of administration of oxytocin and
placebo (P= 0.001). Furthermore, path analysis showed that the NAA differences in the vmPFC triggered increases in the task-
dependent fMRI signals in the vmPFC, which consequently led to improvements in the socio-communication difﬁculties associated
with autism. The present study suggests that the beneﬁcial effects of oxytocin are not limited to the autistic behavior elicited by our
psychological task, but may generalize to other autistic behavioral problems associated with the vmPFC.
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INTRODUCTION
Cumulative evidence has demonstrated that oxytocin signiﬁcantly
affects social and afﬁliated behaviors.1–10 Although oxytocin may
also promote aggression and other antisocial behaviors in certain
circumstances,1,11,12 previous studies have suggested the enhan-
cing effect of oxytocin on social behavior in neuropsychiatric
disorders, such as autism spectrum disorders (ASD).13–19
To evaluate the potential therapeutic effects of oxytocin on the
social deﬁcits associated with ASD, we conducted a double-blind,
cross-over, randomized controlled trial by administering a single
dose of oxytocin to 40 high-functioning men with ASD. We then
performed both functional magnetic resonance imaging (fMRI)
and 1H-magnetic resonance spectroscopy (1H-MRS). As the main
outcome of the clinical trial, we recently reported that intranasal
oxytocin increased the frequency of judgments based on non-
verbal communication information by increasing originally dimin-
ished brain activity using fMRI.20 This ﬁnding is concordant with
the results from prior behavioral studies that reported the
beneﬁcial effects of oxytocin on the social deﬁcits associated
with ASD.19,21–25 However, this signiﬁcant increase in originally
diminished brain activity was quantiﬁed as a change in the blood-
oxygen-level-dependent signal during a socio-communication
psychological task measured by fMRI. Thus, it remains unknown
whether there are the effects of oxytocin on neurochemical that
preceded the effects of oxytocin observed during fMRI.
To address this issue, we aimed to identify the neurochemical
inﬂuence of oxytocin not directly related to any psychological
task, assuming that such inﬂuence would trigger a task-speciﬁc
fMRI signal change. Using 1H-MRS, we examined the inﬂuence of
oxytocin on N-acetylaspartate (NAA) levels. Altered NAA levels
measured with 1H-MRS are thought to be one of the most robust
metabolite abnormalities underlying the neurochemical aspects
of ASD pathophysiology.26,27 Together with its derivative, NAA
synthesized in neurons acts on endothelial cells and modulates
regional blood ﬂow to supply energy to neurons.28 Thus, although
the NAA levels are also inﬂuenced by the density of neurons in the
region,29 the regional levels of NAA or differences in these levels
reﬂect the regional demand of neuronal energy.30,31
A number of previous studies have demonstrated that the
ventromedial prefrontal cortex (vmPFC)/anterior cingulate cortex
(ACC) is involved in a variety of social cognitive components
disturbed in individuals with ASD, such as empathy, emotion
recognition and theory of mind.32–34 In fact, a line of previous fMRI
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and 1H-MRS studies demonstrated the dysfunction of this region
in individuals with ASD.26,34–37 Additionally, our recent systematic
screening and meta-analysis showed that the vmPFC/ACC
has received the most attention in 1H-MRS studies of ASD.26 In
addition, previous studies have suggested that the vmPFC/ACC is
an area greatly affected by oxytocin.15,24,38,39 Therefore, we
examined the vmPFC/ACC40 in the present clinical trial because
it is involved in the pathophysiology of disturbed social cognition
in individuals with ASD and is most sensitive to oxytocin.
In this context, we hypothesized that the inﬂuence of oxytocin
on NAA levels in the vmPFC/ACC underlies our recently reported
fMRI signal changes in the same brain region and the associated
changes in behavior. If there are task-independent oxytocin’s
inﬂuences on neurochemical that underlie task-dependent blood-
oxygen-level-dependent signal changes, this would support the
possibility of broad clinical use of oxytocin in individuals with ASD.
To test this possibility, we measured the NAA levels in the same
clinical trial in the vmPFC/ACC immediately after the fMRI
measurement in both the oxytocin and placebo conditions after
a 1-week interval (Figures 1 and 2). We examined the relation-
ship between the inﬂuence of oxytocin on the NAA levels and
the oxytocin-induced changes in the task-dependent fMRI signal.
We then conducted a path analysis to clarify the relationships
between the oxytocin and NAA levels, the fMRI signal change and
the observed behavioral changes.
MATERIALS AND METHODS
Participants and diagnoses
We used 1H-MRS, an outcome measure of the clinical trial
(UMIN000002241/000004393), to assess the relationship between the
inﬂuence of oxytocin on the neurochemicals measured by 1H-MRS and the
oxytocin-induced changes in fMRI signals, which was recently reported as a
main outcome of the clinical trial.20 Therefore, the descriptions of the study
participants, how the sample size was determined and the diagnostic
protocol are detailed in our previous paper (see the eMethods section
‘Participants’ and ‘Diagnosis’) (Supplementary Figure 1).20 Brieﬂy, of the
323 individuals with probable ASD who visited The University of Tokyo
Hospital or Showa University Karasuyama Hospital between 1 November
2009 and 30 April 2011, 40 high-functioning ASD men participated
because of their ﬁrm diagnosis, age (⩾20 years), full-scale intelligence
quotient (480) and written consent. Of the 33 participants included in the
main analysis in the recent fMRI report,20 two participants were also
excluded from the main analysis here because of the low quality 1H-MRS
spectra (see the eMethods section ‘Participants’).
Randomized and masked drug administration
The method used for randomizing intranasal administration has
been described elsewhere.20 Brieﬂy, this study adopted a randomized,
placebo-controlled, double-blind, within-subjects cross-over experi-
mental design. The individuals with ASD received a single dose of
oxytocin (24 IU; Syntocinon-Spray, Novartis, Basel, Switzerland)41–43
or placebo at a 1-week interval in a pseudo-random order 40min
before each MR scanning session (see the eMethods section ‘Drug
administration’).
Structural MRI acquisition, 1H-MRS acquisition and spectrum
quantiﬁcation
The scanning protocols for the structural MRI and 1H-MRS acquisition, post-
processing procedures and quantiﬁcation of the 1H-MRS spectra were the
same as in our previous studies40,44 (see the eMethods section ‘Structural
MRI acquisition’). Brieﬂy, MRI data were obtained using a 3-T scanner (GE
Signa HDxt, Waukesha, WI, USA). A stimulated echo acquisition model was
applied to obtain the proton MR spectrum from a volume-of-interest (VOI)
at the vmPFC. All spectra were quantiﬁed with LCModel (version 6.1-4F,
Stephen Provencher, Oakville, ON, Canada), and the quality of each
spectrum was assessed for inclusion in the analysis (see the eMethods
sections ‘1H-MRS acquisition’, ‘Spectrum quantiﬁcation’ and ‘Spectrum
quality’). Because we had an a priori hypothesis for the inﬂuence of oxytocin
on NAA levels, we also conducted an exploratory analysis of NAA and NAA
plus N-acetylaspartylglutamate levels. For the exploratory analyses, we also
measured other major metabolites, including creatine, glutamine plus
glutamine, myo-inositol and choline-containing compounds.
Tissue segmentation within the VOI
Three-dimensional fast spoiled gradient-echo (3D-FSPGR) images were
used to calculate the volumes of different tissue types (that is, the
gray matter volume, the white matter volume and the cerebrospinal
ﬂuid) using the segmentation tool in SPM8 (www.ﬁl.ion.ucl.ac.uk/spm). The
method used for tissue segmentation was the same as in our previous
studies (see the eMethods section ‘Tissue segmentation within VOI’).40,44
fMRI task/stimuli, scanning and analysis
The fMRI task, stimuli, scanning45,46 and analysis20 have been reported
in our recent publications. Details are provided in the Supplementary
Information (see the eMethods section ‘fMRI task and stimuli’ and ‘fMRI
scanning’).
Extraction of fMRI signals from the exact location for the 1H-MRS
VOI and mPFC regions
Because it is important to examine metabolite/fMRI signal relationships in
the same anatomical area, the average fMRI signal change was calculated
for the 1H-MRS VOI, cubic with 20 × 20 × 20mm (center of the VOI: x= 0,
y= 42, z=4, the Montreal Neurological Institute coordinates). The effect of
oxytocin on the fMRI signal change from the 1H-MRS VOI was examined by
comparing the average fMRI signal between the oxytocin and placebo
sessions using a paired t-test. Further, the potential associations between
the oxytocin-induced fMRI signal change in the VOI and the change in
socio-communication behavior were also investigated using Pearson’s
correlation analysis (that is, judgment of others’ hostility primarily based
on non-verbal communicative cues, such as facial expression and voice
prosody, rather than the verbal content of speech). For exploratory
purposes, we also extracted the average fMRI signal change from the two
brain regions indicated by recently published fMRI data from the present
clinical trial that exhibited signiﬁcant effects from oxytocin administration,
and these changes were associated with the socio-communication
behavior described elsewhere (see the eMethods section ‘fMRI task and
stimuli’).20 The ﬁrst area was the vmPFC/ACC (x=2, y=34, z=8), which
partially overlapped with the 1H-MRS VOI, and the second area was the
dorsomedial prefrontal cortex (x= 0, y=30, z= 52), which did not overlap
with the VOI.
12 min
7 min
3.6 (2.8) min
fMRI scan
1H-MRS scan
Scan Interval 
(mean (SD))
Time
Figure 1. Experimental design. Relationship between the timing
of the 12-min functional magnetic resonance imaging (fMRI) scan
and the 7-min magnetic resonance spectroscopy (MRS) scan. The
interval between the end of the fMRI scan and the start of the
MRS scan was 3.6± 2.8 (mean± s.d.) min. During the fMRI scan,
the participants were asked to make a ‘friend or foe’ judgment of
the actor in each movie based on the socio-communication content
in which the verbal and non-verbal information conﬂicted.
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Statistical analysis
All statistical analyses were conducted using the Statistical Package for
Social Science (SPSS) Version 21.0 and Amos Version 21.0 (SPSS Inc.,
Chicago, IL, USA). To assess the potential differences in the tissue
composition within the VOIs, the spectrum quality and the metabolite
levels between oxytocin and placebo sessions, we conducted paired
t-tests.
Regression analyses between 1H-MRS and fMRI signals
Single linear regression analyses were performed to ascertain the effects of
metabolite level differences between the oxytocin and placebo sessions
and the extracted fMRI signal change in the VOI and two mPFC regions.
Because we had an a priori hypothesis that differences in NAA levels
between oxytocin and placebo sessions underlie the fMRI signal changes
extracted from the 1H-MRS VOI in the vmPFC, the statistical threshold was
set at Po0.05 for the VOI and at Po0.025 ( = 0.05/2, brain regions) for
the other mPFC regions.
The effects of NAA level differences between the two pharmacological
sessions on the behavioral changes during the fMRI task, which was
signiﬁcantly associated with the fMRI signal change in the 1H-MRS VOI (see
Results), were also examined using a single linear regression analysis by
regressing out the fMRI signal change in the VOI. The statistical threshold
was set at Po0.05.
The statistical analysis of the associations between the other metabolite
level differences with the fMRI signal is described in the Supplementary
Information (see the eMethods section ‘Relationship between the inﬂuence
of oxytocin on other metabolite levels and oxytocin-induced fMRI signal
change’).
Assessing the effects of potential confounding factors on the
relationship between 1H-MRS and fMRI signals
The time interval between the fMRI and 1H-MRS scans may have inﬂu-
enced the relationship between oxytocin–placebo differences in NAA
levels and fMRI signal changes. Thus, we subtracted the interval between
the fMRI and 1H-MRS scans within each session and calculated the
difference in the intervals between the two different pharmacological
sessions. This variable was used to control for the effect of differences in
the timing schedule in the trials.
The effects of the order of drug administration were assessed by
conducting two regression analyses in the two independent groups: the
group in which oxytocin was administered ﬁrst and the other group in
which placebo was administered ﬁrst. Then, the difference in the
regression coefﬁcient between the two groups was assessed using Fisher’s
r to z transformation. To test whether the NAA–fMRI signal association
remained after controlling for the effects of drug administration order, a
single linear regression analysis of the oxytocin–placebo differences in
NAA levels and fMRI signal changes was conducted in which the oxytocin/
placebo administration order was a covariate (see the eMethods section
‘Explore whether both the oxytocin administered ﬁrst group and the
placebo administered ﬁrst groups preserve signiﬁcant NAA/fMRI signal
relation').
In addition, we examined whether the relationship between NAA levels
and fMRI signal changes was preserved after including participants who
were excluded from the main analysis because of psychotropic medica-
tions or unusual behavior during the fMRI task (see the eMethods section
‘Exploring whether the result is preserved after expanding participants’).
Path analysis
A path analysis was conducted to elucidate the multiple relationships
between the inﬂuences of oxytocin on the NAA levels, the oxytocin-
induced changes in fMRI signals and the effects of oxytocin on socio-
communication behavior, with a standard maximum likelihood estimation.
Pathways between these three variables were proposed and expressed
quantitatively as path coefﬁcients. The models constructed can be evalu-
ated using multiple measures. The measures used were the goodness-of-ﬁt
index (GFI), a measure of the overall model ﬁt, the adjusted GFI, which is
the GFI adjusted for the degrees of freedom used to evaluate the overall
L L
X = 0 Y = 42 Z = 4
Chemical shift (ppm)
3
6
t value
4.0 3.0 2.0 1.0
NAAG
4.0 3.0 2.0 1.0
NAA
NAAG
NAA
vmPFC/ACC
(NVJ > VJ) Oxytocin > (NVJ > VJ) Placebo
Figure 2. Anatomical details between the 1H-magnetic resonance spectroscopy (1H-MRS) volume-of-interest (VOI) and functional magnetic
resonance imaging (fMRI) signal change. (a) Brain regions that showed a signiﬁcant effect of oxytocin on the fMRI signal associated with
socio-communication behavior (non-verbal communication information-based judgment (NVJ)-speciﬁc activity4verbal communication
information-based judgment (VJ)) (that is, the ventromedial prefrontal/anterior cingulate cortices (vmPFC/ACC) and the dorsomedial
prefrontal cortex (dmPFC), Po0.001, uncorrected for the purpose of presentation) are overlaid on orthogonal slices. Gray squares represent
the 1H-MRS VOIs (20 × 20 × 20mm). Representative spectrum of (b) oxytocin and (c) placebo sessions in a study participant as ﬁt by the
LCModel.
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model ﬁt, and the Akaike information criteria. If the GFI and adjusted GFI
values are greater than 0.90, the model is considered to have a good ﬁt.
The Akaike information criteria is a measure that compares more than two
models with a good ﬁt; a smaller value indicates a good ﬁt. The ﬁtness of
residuals was assessed using the root mean square error of approximation
(RMSEA), which is based on the non-centrality parameter, and speciﬁcally
considers the approximation error. For the RMSEA, valueso0.08 indicate a
good ﬁt. In general, when the model obtains more than two good scores,
including the RMSEA, the model is considered to have a good ﬁt.
RESULTS
Relationship between the inﬂuence of oxytocin on NAA levels and
oxytocin-induced fMRI signal changes
A paired t-test did not detect a signiﬁcant difference in the
spectral quality or tissue composition between the oxytocin and
placebo sessions (P40.088) (see the eResults section ‘Difference in
spectral quality and tissue composition between two sessions’).
Although signiﬁcant differences in the NAA levels between the
oxytocin and placebo conditions were not detected (t30 = 1.315,
P= 0.198; Supplementary Table 2), a linear regression analysis
demonstrated a signiﬁcant relationship between the inﬂuence of
oxytocin on NAA levels and the oxytocin-induced changes in the
fMRI signal from the vmPFC VOI (R= 0.540, P= 0.002, n= 31;
Figure 3a). It should be noted that the NAA–fMRI signal relation-
ship was also observed with NAA+N-acetylaspartylglutamate, an
alternative measure of NAA and its derivatives, instead of NAA
alone (R= 0.439, P= 0.013, n= 31; Supplementary Figure 2).
A signiﬁcant NAA–fMRI signal relationship was also observed in
the vmPFC/ACC region (R= 0.425, P= 0.017, n= 31; Figure 3b), but
was not preserved in the dorsomedial prefrontal cortex after
correction for multiple comparisons (R= 0.384, P= 0.033, n= 31;
Figure 3c). Importantly, although the location of the 1H-MRS VOI
was not identical to that of the activation peak in the vmPFC/ACC
that was detected in our recently published fMRI data from the
present clinical trial,20 we also detected the same effects of
oxytocin on the fMRI signal in the 1H-MRS VOI (that is, signiﬁcantly
increased fMRI signal, t30 = 4.875, Po0.001 and a signiﬁcant
positive correlation with increased use of judgments based on
non-verbal communicative cues, R= 0.853, Po0.001, n= 31;
Supplementary Figure 3).
The association between the fMRI signals and NAA levels
remained signiﬁcant in an additional regression analysis that
controlled for the difference in the fMRI-1H-MRS scan interval
between the oxytocin and placebo sessions (R= 0.550, P= 0.006,
n= 31), which indicated that this relationship does not depend on
the time interval between the fMRI and 1H-MRS scans.
Furthermore, no signiﬁcant difference in the regression
coefﬁcient between the group in which oxytocin was adminis-
tered ﬁrst and the group in which placebo was administered ﬁrst
was observed (R= 0.237 and R= 0.737, respectively, t= 1.325,
P= 0.196), which indicated that there was no signiﬁcant carry-over
effect. In addition, the association between the fMRI signals and
NAA levels also remained in the regression analysis that controlled
for differences in the administration order (R= 0.618, P= 0.001,
n= 31), which indicated that the relationship does not rely on the
order of drug administration. These ﬁndings suggest that possible
neuronal changes during the 1-week interval are not necessary to
observe the association between the NAA levels and the fMRI
signal.
Furthermore, additional analyses demonstrated that the rela-
tionship between NAA and fMRI signal was preserved even when
the subjects who were on medication or exhibited unusual
behavior during the fMRI tasks were included (Po0.014) (see the
eResults section ‘Relationship between oxytocin’s inﬂuence on the
other metabolite levels and the oxytocin-induced fMRI signal
change’). In addition, associations between other metabolite levels
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Figure 3. Relationships between the oxytocin-induced differences in 1H-magnetic resonance spectroscopy (1H-MRS) measures and the
changes in functional magnetic resonance imaging (fMRI) signal. Scatterplots show the relationships between the oxytocin-induced
N-acetylaspartate (NAA) differences (NAA levels at oxytocin (OT) sessions minus NAA levels at placebo (PL) sessions) and the task-evoked fMRI
signal changes in (a) the volume-of-interest (VOI), (b) the ventromedial prefrontal cortex (vmPFC)/anterior cingulate cortex (ACC) and (c) the
dorsomedial prefrontal cortex (dmPFC). No signiﬁcant relationship was detected between the changes in the fMRI signal and the differences
in (d) creatine (Cre), (e) choline-containing compounds (Cho), (f) glutamine and glutamate (Glx) or (g) myo-Inositol (mI) levels.
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and fMRI signal were not observed, including creatine (Figure 3d),
choline-containing compounds (Figure 3e), glutamine plus gluta-
mine (Figure 3f) and myo-inositol (Figure 3g) (P40.172).
Statistical conﬁrmation of the hypothesized model
Although a correlation analysis demonstrated that the inﬂuence of
oxytocin on NAA levels was signiﬁcantly related to an increased
frequency of judgments based on non-verbal information
(R= 0.454, P= 0.010, n= 31; Supplementary Figure 3), no signiﬁ-
cant relationship between these parameters was observed when
the fMRI signal change was regressed out (R= 0.124, P= 0.515),
which suggests that the inﬂuence of oxytocin on NAA levels is not
directly linked to oxytocin-induced increases in the frequency of
judgments based on non-verbal information. Thus, we hypothe-
sized that differences in NAA levels underlie the fMRI changes and
associated behavioral changes. A path analysis demonstrated that
the hypothesized model had satisfactory indices of the GFI
(GFI = 0.990, adjusted GFI = 0.940 and a RMSEAo0.001; Table 1).
Furthermore, among the possible models that are consistent with
the notion that the oxytocin-induced neural changes (that is,
metabolite level and/or fMRI signal) underlie behavioral change,15
the hypothesized model had the smallest value of Akaike infor-
mation criteria = 10.462. These results suggest that the hypothe-
sized model is the best ﬁt model (Table 1; Figure 4).
DISCUSSION
The crucial ﬁnding in the present study is that the inﬂuence
of oxytocin on NAA levels in the vmPFC/ACC, which is not
conﬁned to a speciﬁc psychological task, underlies the oxytocin-
induced increase of originally diminished task-speciﬁc fMRI signal
in the same brain region. Although a single dose of intranasal
oxytocin administration did not signiﬁcantly alter the NAA levels,
the present ﬁndings suggest an important role for the vmPFC/ACC
in the neural mechanisms of oxytocin-induced behavioral
improvements in the socio-communication deﬁcits associated
with ASD. Importantly, the current ﬁndings cannot be directly
extended to female subjects with ASD, ASD subjects with
intellectual disabilities or typically developed individuals.
The fMRI signal change induced by oxytocin was related to
differences in the NAA levels, but not with other metabolite
changes. Regional NAA levels are determined by both static
structural factors (for example, regional neuronal density29) and
dynamic functional factors (for example, synthesis of NAA in each
neuron that responds to neuronal energy demand).30,38 In the
current study, we obtained the NAA levels in two pharmacological
conditions with a 1-week interval in the same brain region in the
same individual, suggesting that these changes are less likely due
to structural changes. The sub-analyses in the current study also
indicated no signiﬁcant difference in the association between NAA
levels and fMRI signal between the two groups that differed in the
order of oxytocin administration. Although a 1-week interval may
cause slight structural changes, the current results indicate that
the signiﬁcance of the relationship between the fMRI signal
change and the differences in NAA levels remained regardless of
the 1-week interval. It is possible for oxytocin-associated structural
changes to occur within the interval between oxytocin adminis-
tration and the 1H-MRS scan (mean± s.d.: 87.5 ± 10.3 min), but it
may be more likely that the difference in the NAA levels between
the different pharmacological conditions reﬂects a difference in
dynamic function rather than static structural factors. Previous
studies also support this notion, suggesting that repeated
evaluations of the NAA levels within a short interval (that is,
3–4min) in the same brain region of the same individual may
change because of dynamic changes in neuronal energy
demand.30 Previous studies have also reported potential rapid
changes in NAA levels (for example, within 10 min).30 Prior studies
have also reported that a single intranasal administration of
oxytocin induced an increase in plasma oxytocin levels within
30–150 min.47 We measured the NAA levels ~ 90min after the
intranasal administration of oxytocin/placebo. Thus, it can be
assumed that there was sufﬁcient time for changes in the NAA
levels to occur between the oxytocin administration and the 1H-
MRS scan, and that there may be an effect of oxytocin during the
1H-MRS scan. Taken together, the current ﬁnding suggests that
intranasal oxytocin may inﬂuence the vmPFC/ACC neuronal
energy demand that modulates the differences in NAA levels
underlying the fMRI signal changes.
In the present study, we aimed to scan the participants during
the period when oxytocin has the greatest inﬂuence in the brain.
To achieve this purpose, we have traded off the temporal
speciﬁcity against spatial speciﬁcity. Thus, we cannot conclude
that the association of NAA levels with fMRI signal is regionally
speciﬁc to the vmPFC/ACC by the current single-voxel 1H-MRS
without a control VOI. However, the current study ﬁndings are
consistent with the hypothesis that oxytocin may affect social
interaction through the modulation of vmPFC/ACC function as a
key site of a prefrontal-limbic circuit15,20,39,48,49 and reports a new
result on the effect of oxytocin at the neurochemical level.
Because we obtained metabolite levels after the fMRI scan, task-
speciﬁc neural activation may have affected NAA levels. Thus, both
the NAA levels and fMRI signal change may reﬂect neural
Table 1. Results of the path analysis
Model RMSEA GFI AGFI AIC
Two paths model
NAA→ fMRI signal→behaviora o0.001 0.990 0.940 10.462
fMRI signal→NAA→behavior 0.660 0.800 − 0.198 24.054
NAA and fMRI
signal→behavior
0.558 0.837 0.024 20.333
One path model
NAA→behavior 0.383 0.832 0.497 18.794
fMRI signal→behavior 0.611 0.729 0.188 32.387
Abbreviations: AGFI, adjusted goodness-of-ﬁt index; AIC, Akaike informa-
tion criterion; fMRI, functional magnetic resonance imaging; GFI,
goodness-of-ﬁt index; NAA, N-acetylaspartate; RMSEA, root mean square
error of approximation. aOptimal model.
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0.540
 NAA level   fMRI signal  behavior
0.704
 fMRI signal  behavior
0.00 0.00
 fMRI signal
 NAA level
 behavior
 NAA level  behavior
NAA level
0.704
0.00
0.704
0.00
Figure 4. Statistical conﬁrmation of the hypothesized model. (a) A
hypothesized model of the relationship between NAA level
differences, fMRI signal changes and behavioral changes. Path
coefﬁcients (that is, standardized partial regression coefﬁcients) are
written above each arrow. (b) The model shown is more likely
compared with all other possible models that are based on the
hypothesis that oxytocin-induced behavioral changes are mediated
by neural changes.
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activation due to the speciﬁc psychological task. There are two
arguments against this potential confound. First, NAA levels have
previously been suggested to decrease during stimulation and
begin to recover to baseline levels soon after the stimulation ends
(that is, 5–6min).30 In the current study, there was a 3.6-min
interval between the end of the fMRI scan and the start of the
1H-MRS scan, which may be an adequate time to return to base-
line NAA levels during the 7-min 1H-MRS scan. Thus, it is expected
that there was little residual inﬂuence of the stimulation during
fMRI on the NAA levels. In addition, the path analysis suggested
that our hypothesized model statistically conforms more to three
variables, including the NAA level differences, the fMRI signal
changes and the behavioral changes, compared with the model in
question, which assumes that the NAA differences were induced
by fMRI changes. Although a limited number of previous studies
have investigated the relationship between metabolite levels
measured by MRS and the fMRI signal,50–52 taken together, the
current ﬁndings suggest that the inﬂuence of oxytocin on NAA
levels may underlie the fMRI signal and behavioral changes.
Although no signiﬁcant difference was observed in the
metabolite levels between the oxytocin and placebo sessions,
the global trend was that all metabolites except choline-
containing compounds were higher in the placebo session
compared with the oxytocin session, which suggests that oxytocin
induced global physiological changes in the brain. Multiple
regression analysis showed a signiﬁcant relationship between
the differences in all major metabolites (NAA, creatine, myo-
inositol, choline-containing compounds and glutamine plus
glutamine) and fMRI signal changes; however, this association
disappeared when NAA was excluded from the analysis (see
eMethods and eResults). These results suggest that differences in
NAA levels have an essential role in predicting fMRI signal change.
However, because in vivo NAA is associated with water
transportation, it is possible that oxytocin administration induced
global physiological changes, such as global changes in brain
water content. Future studies that address whether oxytocin
induces global physiological effects in the brain should be
performed.
Other factors may explain the association between the NAA/
fMRI signal change other than oxytocin, such as motion artifact,
system drift over time and global changes in the participants.
Among these factors, we conﬁrmed that there was no signiﬁcant
effect of motion artifacts during fMRI on the association between
the NAA/fMRI signal changes. Magnetic ﬁeld inhomogeneity in our
scanner was monitored with daily basic quality control. In
addition, there was no signiﬁcant inﬂuence of system drift over
time on the association between the NAA/fMRI signal change (see
eMethods and eResults). In terms of global changes in the
participants, we scanned all participants under approximately the
same conditions in the same scanner at nearly the same time;
further, all pairs of sessions were performed at a 1-week interval.
We conﬁrmed that there was no exacerbation of mental health
problems during this clinical trial in any of the participants by a
trained psychiatrist (HY) before each MRI scan during the sessions,
which suggests that there were no global changes in the
participants at the clinical level.
The absence of a signiﬁcant effect of oxytocin on NAA levels
prevents us from reporting the usability of 1H-MRS as a functional
paradigm to detect the effect of oxytocin on the brain. A potential
explanation for the absence of group level effects of oxytocin on
NAA levels is that heterogeneity in the pathophysiology of ASD
among participants may result in heterogeneous responses to
oxytocin administration. For example, the single nucleotide
polymorphism rs2254298A in the oxytocin receptor gene (OXTR),
a risk allele for ASD in the Asian population,53 is associated with
small gray matter volume in the vmPFC/ACC.49 Variance in the
CD38 gene, which codes for a protein involved in oxytocin
secretion processes,6 inﬂuences oxytocin plasma levels, social
behavior and the response to externally administered oxytocin.54
In sum, it is assumed that individuals with ASD who have risk
alleles in the OXTR and those in the CD38 genes exhibit different
responses to oxytocin, and heterogeneity in the potential etiology
may result in the absence of group level effects of oxytocin.
However, to address this speculation and explore other possibi-
lities, future studies that examine the relationship between
genetic polymorphisms and the response to externally adminis-
tered oxytocin should be performed.
The current study demonstrated that the inﬂuence of oxytocin
on NAA levels in the vmPFC/ACC does not depend on speciﬁc
psychological tasks, but instead underlies the oxytocin-induced
increase of originally diminished task-speciﬁc fMRI signals in the
vmPFC/ACC in adult males with ASD. These ﬁndings suggest the
possibility that a single dose of intranasal oxytocin induces a
general (that is, task independent) change in the regional
neuronal energy demand in the vmPFC/ACC. Because this brain
region is putatively involved in a variety of cognitive deﬁcits
observed in individuals with ASD,34–36 the results of the present
study indicate that the potential beneﬁts of oxytocin are not
limited to speciﬁc autistic behavior elicited in a psychological task,
but may be expanded to a relatively broad range of autistic
behavioral problems involved in vmPFC/ACC dysfunction in adult
males with high-functioning ASD.
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